Opinion|Videos|January 22, 2025

Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.

Video content above is prompted by the following:

  1. How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
    1. Include in your discussion the EASL 2024 abstract.

Latest CME